SuperworthCRISPR Therapeutics shares outstanding CRSP
Diluted shares outstanding, averaged over each quarter, from 2015.
- Latest quarter, to Jun 30, 2026
- 96.5M
- On a year earlier
- +10.8%
- more shares
CRISPR Therapeutics had 96.5M diluted shares outstanding on average in Q2 FY26, the quarter to Jun 30, 2026.
That is 10.8% more than a year earlier, so each share owns a little less of the company.
Shares outstanding over time
Fiscal year by fiscal year
| Fiscal year | Shares, fourth quarter | Change |
|---|---|---|
| FY2025 | 95.3M | +11% |
| FY2024 | 85.5M | +7% |
| FY2023 | 79.7M | +2% |
| FY2022 | 78.3M | +2% |
| FY2021 | 76.6M | +8% |
| FY2020 | 71.3M | +18% |
| FY2019 | 60.2M | +17% |
| FY2018 | 51.7M | +28% |
| FY2017 | 40.5M | +24% |
| FY2016 | 32.6M | +490% |
| FY2015 | 5.5M | n/a |
Each fiscal year is the twelve months to its fourth quarter, shown as the fourth quarter's average share count.
Quarter by quarter
| Quarter | Ended | Shares outstanding | On a year earlier |
|---|---|---|---|
| Q2 FY26 | 96.5M | +11% | |
| Q1 FY26 | 96.1M | +12% | |
| Q4 FY25 | 95.3M | +11% | |
| Q3 FY25 | 91.3M | +7% | |
| Q2 FY25 | 87.1M | +3% | |
| Q1 FY25 | 85.9M | +5% | |
| Q4 FY24 | 85.5M | +7% | |
| Q3 FY24 | 85.2M | +7% | |
| Q2 FY24 | 84.9M | +7% | |
| Q1 FY24 | 81.8M | +4% | |
| Q4 FY23 | 79.7M | +2% | |
| Q3 FY23 | 79.4M | +2% |
What the shares outstanding tells you
Diluted shares outstanding, averaged over the period. Fewer shares means each one owns more of the company.
A falling count usually means buybacks. A rising one means stock pay, acquisitions paid in shares or new shares sold.
More on CRISPR Therapeutics
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.